Post Profile






First line combination therapy improves progression-free survival in advanced lung cancer

(European Society for Medical Oncology) A new combination therapy for the first line treatment of advanced non-squamous non-small-cell lung cancer (NSCLC) improves progression-free survival (PFS), according to results of the phase III IMpower150 trial presented at the ESMO Immuno Oncology Congress 2017.
read more

share

Related Posts


Adding radiation to chemotherapy may dramatically improve survival for advanced NSCLC

Diseases & Conditions / Cancer : ScienceDaily: Cancer

Combining radiation therapy with chemotherapy for patients with limited metastatic non-small cell lung cancer (NSCLC) may curb disease progression dramatically when compared to NSCLC patients who only receive chemotherapy, according...

Durvalumab improves progression-free survival in stage III lung cancer

Health : EurekAlert: Health

(European Society for Medical Oncology) Durvalumab improves progression-free survival in patients with locally advanced, unresectable stage III lung cancer, according to late-breaking results from the phase III PACIFIC trial present...

Osimertinib improves progression-free survival in patients with EGFR mutated lung cancer

Health : EurekAlert: Health

(European Society for Medical Oncology) Osimertinib improves progression-free survival by 54% compared to standard first line therapy in patients with EGFR mutated non-small-cell lung cancer (NSCLC), according to late-breaking resul...

Osimertinib improves progression-free survival in Asian EGFR-mutated lung cancer patients

Health : EurekAlert: Health

(European Society for Medical Oncology) Osimertinib improves progression-free survival compared to standard first line therapy in Asian patients with EGFR-mutated non-small-cell lung cancer (NSCLC), according to the Asian subset ana...

MEK inhibition in KRAS-mutant NSCLC did not improve survival

Diseases & Conditions / Cancer : EurekAlert: Cancer

(European Society for Medical Oncology) MEK inhibitor selumetinib in combination with docetaxel does not improve progression free or overall survival in individuals with KRAS-mutant non-small-cell lung cancer (NSCLC), according to d...

Comments


Copyright © 2016 Regator, LLC